Pfizer taps CytoReasons machine learning platform for drug discovery

Pfizer taps CytoReason’s machine learning platform for drug discovery

12:36 EST 7 Jan 2019 | Outsourcing-Pharma

CytoReason has today announced a collaboration with Pfizer â as the machine learning company eyes future partnerships with industry leaders to up the accuracy of its models and affect decision-making throughout the drug development pipeline, says CEO.

Original Article: Pfizer taps CytoReason’s machine learning platform for drug discovery

More From BioPortfolio on "Pfizer taps CytoReason’s machine learning platform for drug discovery"